<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Health and Prostate &#187; Drugs</title>
	<atom:link href="http://healthandprostate.com/category/drugs/feed" rel="self" type="application/rss+xml" />
	<link>http://healthandprostate.com</link>
	<description>Benign Prostatic Hyperplasia - Prostate Cancer - Prostatitis</description>
	<lastBuildDate>Fri, 28 Oct 2011 14:09:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
<xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" />
		<item>
		<title>Triptorelin Pamoate</title>
		<link>http://healthandprostate.com/drugs/triptorelin-pamoate</link>
		<comments>http://healthandprostate.com/drugs/triptorelin-pamoate#comments</comments>
		<pubDate>Fri, 24 Jun 2011 10:18:04 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Chlorpromazine]]></category>
		<category><![CDATA[Estradiol]]></category>
		<category><![CDATA[Metoclopramide]]></category>
		<category><![CDATA[Olanzapine]]></category>
		<category><![CDATA[Risperidone]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1064</guid>
		<description><![CDATA[C64H82N18O13 • Triptorelin pamoate, a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), is an antineoplastic agent. Uses • Prostate Cancer Triptorelin pamoate is used for the palliative treatment of advanced prostate cancer. The drug currently is considered alternative therapy when orchiectomy or estrogen therapy is not appropriate or is unacceptable to the patient. In a randomized, active-control trial in men with advanced prostate cancer who received triptorelin pamoate as a 1-month formulation or another GnRH agonist monthly for 9 months, castration levels of serum testosterone were achieved in 91.2% of triptorelin pamoate patients at day 29 and 97.7% of patients at day 57. Maintenance of castration levels of serum testosterone from day 57 through day 253 was found in 96.% of triptorelin-treated patients. In addition, on day 85 of the study, serum LH concentrations were less than 1 IU/L in 98.% of evaluable patients when measured 2 hours after triptorelin pamoate administration on day 85, indicating desensitization Read more [...]]]></description>
			<content:encoded><![CDATA[C64H82N18O13

• Triptorelin pamoate, a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), is an antineoplastic agent.
Uses
• Prostate Cancer

Triptorelin pamoate is used for the palliative treatment of advanced prostate cancer. The drug currently is considered alternative therapy when orchiectomy or estrogen therapy is not appropriate or is unacceptable to the patient.

In a randomized, active-control trial in men with advanced prostate cancer who received triptorelin pamoate as a 1-month formulation or another GnRH agonist monthly for 9 months, castration levels of serum testosterone were achieved in 91.2% of triptorelin pamoate patients at day 29 and 97.7% of patients at day 57. Maintenance of castration levels of serum testosterone from day 57 through day 253 was found in 96.% of triptorelin-treated patients. In addition, on day 85 of the study, serum LH concentrations were less than 1 IU/L in 98.% of evaluable patients when measured 2 hours after triptorelin pamoate administration on day 85, indicating desensitization <a href="http://healthandprostate.com/drugs/triptorelin-pamoate" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/triptorelin-pamoate/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nilutamide</title>
		<link>http://healthandprostate.com/drugs/nilutamide-2</link>
		<comments>http://healthandprostate.com/drugs/nilutamide-2#comments</comments>
		<pubDate>Fri, 24 Jun 2011 10:15:18 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Bicalutamide]]></category>
		<category><![CDATA[Flutamide]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1061</guid>
		<description><![CDATA[C12H10F3N3O4 • Nilutamide is a nonsteroidal antiandrogen. Uses • Prostate Cancer Nilutamide is used in combination with orchiectomy in the treatment of metastatic prostate cancer that involves distant lymph nodes, bone, or visceral organs (stage D2). Results of controlled clinical studies in patients with metastatic prostate cancer indicate that nilutamide in combination with orchiectomy slows progression of the disease, relieve bone pain associated with metastatic disease, and improve overall survival rate after long-term therapy (8.5 years). Prostate specific antigen (PSA) concentrations should be determined periodically during nilutamide therapy to monitor therapeutic response, including successful remission or possible progression of cancer. If PSA concentrations increase substantially and consistently during nilutamide therapy, the possibility of clinical progression should be evaluated. Progression noted after gonadal ablation (e.g., orchiectomy) and antiandrogen therapy may represent growth that is not androgen dependent. For patients receiving orchiectomy and nilutamide who Read more [...]]]></description>
			<content:encoded><![CDATA[C12H10F3N3O4

• Nilutamide is a nonsteroidal antiandrogen.
Uses
• Prostate Cancer

Nilutamide is used in combination with orchiectomy in the treatment of metastatic prostate cancer that involves distant lymph nodes, bone, or visceral organs (stage D2). Results of controlled clinical studies in patients with metastatic prostate cancer indicate that nilutamide in combination with orchiectomy slows progression of the disease, relieve bone pain associated with metastatic disease, and improve overall survival rate after long-term therapy (8.5 years).

Prostate specific antigen (PSA) concentrations should be determined periodically during nilutamide therapy to monitor therapeutic response, including successful remission or possible progression of cancer. If PSA concentrations increase substantially and consistently during nilutamide therapy, the possibility of clinical progression should be evaluated. Progression noted after gonadal ablation (e.g., orchiectomy) and antiandrogen therapy may represent growth that is not androgen dependent. For patients receiving orchiectomy and nilutamide who <a href="http://healthandprostate.com/drugs/nilutamide-2" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/nilutamide-2/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mitoxantrone Hydrochloride</title>
		<link>http://healthandprostate.com/drugs/mitoxantrone-hydrochloride</link>
		<comments>http://healthandprostate.com/drugs/mitoxantrone-hydrochloride#comments</comments>
		<pubDate>Fri, 24 Jun 2011 10:13:05 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Etoposide]]></category>
		<category><![CDATA[Prednisone]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1059</guid>
		<description><![CDATA[C22H28N4O6•2HCl DHAD • Mitoxantrone hydrochloride, a synthetic anthracenedione, is an antineoplastic agent. Uses Mitoxantrone is used as a component of combination chemotherapeutic regimens for remission induction in acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL) in adults. The drug also is used in combination with a corticosteroid in the palliative treatment of advanced, symptomatic (i.e., painful) hormone-refractory prostate cancer. Mitoxantrone should be used under the supervision of a qualified physician experienced in therapy with antineoplastic agents. Laboratory and supportive services must be available for hematologic and chemistry monitoring and adjunctive therapies, including anti-infectives; blood and blood products must be available to support patients during the expected period of medullary hypoplasia and severe myelosuppression. Particular care should be given to ensure full hematologic recovery before initiating consolidation therapy (if this treatment is used), and patients should be monitored closely during this phase. According to the manufacturer, Read more [...]]]></description>
			<content:encoded><![CDATA[C22H28N4O6•2HCl

DHAD

• Mitoxantrone hydrochloride, a synthetic anthracenedione, is an antineoplastic agent.
Uses
Mitoxantrone is used as a component of combination chemotherapeutic regimens for remission induction in acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL) in adults. The drug also is used in combination with a corticosteroid in the palliative treatment of advanced, symptomatic (i.e., painful) hormone-refractory prostate cancer.

Mitoxantrone should be used under the supervision of a qualified physician experienced in therapy with antineoplastic agents. Laboratory and supportive services must be available for hematologic and chemistry monitoring and adjunctive therapies, including anti-infectives; blood and blood products must be available to support patients during the expected period of medullary hypoplasia and severe myelosuppression. Particular care should be given to ensure full hematologic recovery before initiating consolidation therapy (if this treatment is used), and patients should be monitored closely during this phase.

According to the manufacturer, <a href="http://healthandprostate.com/drugs/mitoxantrone-hydrochloride" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/mitoxantrone-hydrochloride/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leuprolide Acetate</title>
		<link>http://healthandprostate.com/drugs/leuprolide-acetate</link>
		<comments>http://healthandprostate.com/drugs/leuprolide-acetate#comments</comments>
		<pubDate>Fri, 24 Jun 2011 10:09:38 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Cyclophosphamide]]></category>
		<category><![CDATA[Estradiol]]></category>
		<category><![CDATA[Flutamide]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1049</guid>
		<description><![CDATA[C59H84N16O12•C2H4O2 • Leuprolide acetate, a synthetic nonapeptide analog of naturally occurring porcine or ovine gonadotropin releasing hormone (GnRH, luteinizing hormone releasing hormone, gonadorelin), may be used as an antineoplastic agent and for its endocrine effects. Drug Interactions The manufacturer states there are no reports to date of drug interactions with leuprolide. The manufacturer also states that because leuprolide is a peptide that is mainly degraded by peptidase and not by cytochrome P-450 microsomal enzymes and because of the drug's low degree of protein binding, drug interactions would not be expected to occur with leuprolide. There is some evidence from studies in mice to suggest that the inhibitory effect of leuprolide on spermatogenesis may be used to therapeutic advantage in the prevention of azoospermia or severe oligospermia that frequently results from therapy with cytotoxic agents. In mice receiving combined therapy with leuprolide and cyclophosphamide, testicular damage was less than that observed in animals receiving cyclophosphamide alone. It has been Read more [...]]]></description>
			<content:encoded><![CDATA[C59H84N16O12•C2H4O2

• Leuprolide acetate, a synthetic nonapeptide analog of naturally occurring porcine or ovine gonadotropin releasing hormone (GnRH, luteinizing hormone releasing hormone, gonadorelin), may be used as an antineoplastic agent and for its endocrine effects.
Drug Interactions
The manufacturer states there are no reports to date of drug interactions with leuprolide. The manufacturer also states that because leuprolide is a peptide that is mainly degraded by peptidase and not by cytochrome P-450 microsomal enzymes and because of the drug's low degree of protein binding, drug interactions would not be expected to occur with leuprolide.

There is some evidence from studies in mice to suggest that the inhibitory effect of leuprolide on spermatogenesis may be used to therapeutic advantage in the prevention of azoospermia or severe oligospermia that frequently results from therapy with cytotoxic agents. In mice receiving combined therapy with leuprolide and cyclophosphamide, testicular damage was less than that observed in animals receiving cyclophosphamide alone. It has been <a href="http://healthandprostate.com/drugs/leuprolide-acetate" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/leuprolide-acetate/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leuprolide Acetate: Cautions</title>
		<link>http://healthandprostate.com/drugs/leuprolide-acetate-cautions</link>
		<comments>http://healthandprostate.com/drugs/leuprolide-acetate-cautions#comments</comments>
		<pubDate>Fri, 24 Jun 2011 09:58:33 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Calcium]]></category>
		<category><![CDATA[Danazol]]></category>
		<category><![CDATA[Flutamide]]></category>
		<category><![CDATA[Phenytoin]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1055</guid>
		<description><![CDATA[Leuprolide generally is well tolerated and usual dosages (i.e., 1 mg daily) have been associated with fewer adverse systemic effects than usual dosages (i.e., 3 mg daily) of diethylstilbestrol (DES) (no longer commercially available in the US). The most frequent adverse effects associated with leuprolide therapy are hot flushes in males and females and amenorrhea in females. (See Cautions: Endocrine Effects.) These and other effects secondary to hypoestrogenism are the predominant adverse effects observed in females receiving the drug. The safety profiles of the injection and suspension dosage forms of the drug appear to be similar. A worsening (flare) of signs and/or symptoms of hormone-dependent disease (e.g., endometriosis, prostatic carcinoma) has occasionally occurred during the initial 1-2 weeks of leuprolide therapy (secondary to the initial leuprolide-induced stimulation of pituitary release of gonadotropins and resultant ovarian and testicular steroidogenesis) and then subsided during continued therapy. In males with prostate cancer, this transient exacerbation of signs and/or symptoms Read more [...]]]></description>
			<content:encoded><![CDATA[Leuprolide generally is well tolerated and usual dosages (i.e., 1 mg daily) have been associated with fewer adverse systemic effects than usual dosages (i.e., 3 mg daily) of diethylstilbestrol (DES) (no longer commercially available in the US). The most frequent adverse effects associated with leuprolide therapy are hot flushes in males and females and amenorrhea in females. (See Cautions: Endocrine Effects.) These and other effects secondary to hypoestrogenism are the predominant adverse effects observed in females receiving the drug. The safety profiles of the injection and suspension dosage forms of the drug appear to be similar.

A worsening (flare) of signs and/or symptoms of hormone-dependent disease (e.g., endometriosis, prostatic carcinoma) has occasionally occurred during the initial 1-2 weeks of leuprolide therapy (secondary to the initial leuprolide-induced stimulation of pituitary release of gonadotropins and resultant ovarian and testicular steroidogenesis) and then subsided during continued therapy. In males with prostate cancer, this transient exacerbation of signs and/or symptoms <a href="http://healthandprostate.com/drugs/leuprolide-acetate-cautions" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/leuprolide-acetate-cautions/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leuprolide Acetate: Dosage and Administration</title>
		<link>http://healthandprostate.com/drugs/leuprolide-acetate-dosage-and-administration</link>
		<comments>http://healthandprostate.com/drugs/leuprolide-acetate-dosage-and-administration#comments</comments>
		<pubDate>Fri, 24 Jun 2011 09:54:48 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Flutamide]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1052</guid>
		<description><![CDATA[• Reconstitution and Administration Leuprolide acetate suspension is administered IM, and leuprolide acetate injection is administered subcutaneously. The manufacturer states that the suspension is not intended for self-administration and therefore should be administered under the supervision of a physician. Various dosage forms of the drug have also been administered IV72, 77 and intranasally, but these routes of administration currently are not recommended. Injection sites should be rotated periodically. Leuprolide acetate injection should be inspected visually for particulate matter and discoloration prior to administration. Leuprolide acetate powder for injectable suspension should be reconstituted using only the diluent provided by the manufacturer; other diluents should not be substituted. To reconstitute the suspensions containing 3.75, 7.5, 11.25, or 15 mg of drug per dose, 1 mL of the diluent should be withdrawn from the ampul (using a syringe with a 22-gauge needle) and added to the vial containing the powder for injectable suspension. To reconstitute the suspensions containing Read more [...]]]></description>
			<content:encoded><![CDATA[• Reconstitution and Administration

Leuprolide acetate suspension is administered IM, and leuprolide acetate injection is administered subcutaneously. The manufacturer states that the suspension is not intended for self-administration and therefore should be administered under the supervision of a physician. Various dosage forms of the drug have also been administered IV72, 77 and intranasally, but these routes of administration currently are not recommended. Injection sites should be rotated periodically. Leuprolide acetate injection should be inspected visually for particulate matter and discoloration prior to administration.

Leuprolide acetate powder for injectable suspension should be reconstituted using only the diluent provided by the manufacturer; other diluents should not be substituted. To reconstitute the suspensions containing 3.75, 7.5, 11.25, or 15 mg of drug per dose, 1 mL of the diluent should be withdrawn from the ampul (using a syringe with a 22-gauge needle) and added to the vial containing the powder for injectable suspension. To reconstitute the suspensions containing <a href="http://healthandprostate.com/drugs/leuprolide-acetate-dosage-and-administration" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/leuprolide-acetate-dosage-and-administration/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leuprolide Acetate: Uses</title>
		<link>http://healthandprostate.com/drugs/leuprolide-acetate-uses</link>
		<comments>http://healthandprostate.com/drugs/leuprolide-acetate-uses#comments</comments>
		<pubDate>Fri, 24 Jun 2011 09:53:10 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Danazol]]></category>
		<category><![CDATA[Flutamide]]></category>
		<category><![CDATA[Medroxyprogesterone]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1050</guid>
		<description><![CDATA[• Prostate Cancer Leuprolide acetate is used for the palliative treatment of advanced prostate cancer. The drug currently is considered alternative therapy for patients with inoperable prostatic tumors and/or who are intolerant to estrogen therapy (i.e., those at risk of estrogen-induced thromboembolic and thrombotic disorders, other cardiovascular effects, or other adverse effects) and for patients who refuse orchiectomy and/or estrogen therapy. Most clinical studies with the drug have been performed in patients with prostate cancer clinically diagnosed as stage D2 (i.e., tumor with metastases to distant lymph nodes, bone, and/or viscera). Responses to leuprolide therapy generally have been evaluated based on the criteria of the National Prostatic Cancer Project (NPCP). Leuprolide acetate injection and suspension have been shown to have comparable efficacy and safety in the treatment of advanced prostate cancer. Although direct comparison in clinical trials has not been performed, the safety and efficacy of the 4-month depot injection appear similar to the other leuprolide depot formulations. Read more [...]]]></description>
			<content:encoded><![CDATA[• Prostate Cancer

Leuprolide acetate is used for the palliative treatment of advanced prostate cancer. The drug currently is considered alternative therapy for patients with inoperable prostatic tumors and/or who are intolerant to estrogen therapy (i.e., those at risk of estrogen-induced thromboembolic and thrombotic disorders, other cardiovascular effects, or other adverse effects) and for patients who refuse orchiectomy and/or estrogen therapy. Most clinical studies with the drug have been performed in patients with prostate cancer clinically diagnosed as stage D2 (i.e., tumor with metastases to distant lymph nodes, bone, and/or viscera). Responses to leuprolide therapy generally have been evaluated based on the criteria of the National Prostatic Cancer Project (NPCP). Leuprolide acetate injection and suspension have been shown to have comparable efficacy and safety in the treatment of advanced prostate cancer. Although direct comparison in clinical trials has not been performed, the safety and efficacy of the 4-month depot injection appear similar to the other leuprolide depot formulations. <a href="http://healthandprostate.com/drugs/leuprolide-acetate-uses" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/leuprolide-acetate-uses/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Goserelin Acetate</title>
		<link>http://healthandprostate.com/drugs/goserelin-acetate</link>
		<comments>http://healthandprostate.com/drugs/goserelin-acetate#comments</comments>
		<pubDate>Fri, 24 Jun 2011 09:36:07 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Danazol]]></category>
		<category><![CDATA[Estradiol]]></category>
		<category><![CDATA[Flutamide]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1047</guid>
		<description><![CDATA[C 59H 84N 18O 14 • Goserelin acetate, a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), may be used as an antineoplastic agent and for its endocrine effects. Uses • Prostate Cancer Goserelin acetate is used for the palliative treatment of advanced prostate cancer. Therapy with a GnRH agonist (e.g., goserelin) currently is considered one of several first-line options for hormonal therapy in patients with prostate cancer; other options include orchiectomy, estrogens, and antiandrogens. In controlled clinical studies in patients with advanced prostate cancer, goserelin (3.6 mg administered subcutaneously every 4 weeks) was as effective as orchiectomy as determined by the degree of testosterone suppression, duration of response and survival, and/or objective response rate. Results of several dose-response studies in patients with advanced prostate cancer indicate that pharmacodynamic effects (i.e., reductions in serum testosterone and prostate specific antigen [PSA] concentrations) associated with administration Read more [...]]]></description>
			<content:encoded><![CDATA[C 59H 84N 18O 14

• Goserelin acetate, a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), may be used as an antineoplastic agent and for its endocrine effects.
Uses
• Prostate Cancer

Goserelin acetate is used for the palliative treatment of advanced prostate cancer. Therapy with a GnRH agonist (e.g., goserelin) currently is considered one of several first-line options for hormonal therapy in patients with prostate cancer; other options include orchiectomy, estrogens, and antiandrogens.

In controlled clinical studies in patients with advanced prostate cancer, goserelin (3.6 mg administered subcutaneously every 4 weeks) was as effective as orchiectomy as determined by the degree of testosterone suppression, duration of response and survival, and/or objective response rate. Results of several dose-response studies in patients with advanced prostate cancer indicate that pharmacodynamic effects (i.e., reductions in serum testosterone and prostate specific antigen [PSA] concentrations) associated with administration <a href="http://healthandprostate.com/drugs/goserelin-acetate" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/goserelin-acetate/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Goserelin Acetate: Dosage and Administration</title>
		<link>http://healthandprostate.com/drugs/goserelin-acetate-dosage</link>
		<comments>http://healthandprostate.com/drugs/goserelin-acetate-dosage#comments</comments>
		<pubDate>Fri, 24 Jun 2011 09:31:46 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Alendronate]]></category>
		<category><![CDATA[Bicalutamide]]></category>
		<category><![CDATA[Estradiol]]></category>
		<category><![CDATA[Flutamide]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1043</guid>
		<description><![CDATA[• General Goserelin acetate is administered as a biodegradable implant subcutaneously into the upper abdominal wall, under the supervision of a clinician. Implants containing 3.6 mg of goserelin are administered every 4 weeks. When indicated, implants containing 10. mg of goserelin are administered every 12 weeks. 2 6 Although a delay of a few days is permitted, the manufacturer states that every effort should be made to adhere to the recommended schedule. A local anesthetic may be given prior to implantation of goserelin. In the event that the implant needs to be removed, it may be located by ultrasound. The manufacturer's labeling should be consulted for proper methods of administration and associated precautions. Dosage of goserelin acetate is expressed in terms of goserelin. • Prostate Cancer For the palliative treatment of advanced prostate cancer, the usual dosage of goserelin in men is 3.6 or 10.8 mg implanted subcutaneously every 4 or 12 weeks, respectively. For this indication, goserelin is intended for long-term administration unless it is clinically inappropriate. When Read more [...]]]></description>
			<content:encoded><![CDATA[•  General
Goserelin acetate is administered as a biodegradable implant subcutaneously into the upper abdominal wall, under the supervision of a clinician. Implants containing 3.6 mg of goserelin are administered every 4 weeks.  When indicated, implants containing 10. mg of goserelin are administered every 12 weeks. 2 6 Although a delay of a few days is permitted, the manufacturer states that every effort should be made to adhere to the recommended schedule. A local anesthetic may be given prior to implantation of goserelin.  In the event that the implant needs to be removed, it may be located by ultrasound.  The manufacturer's labeling should be consulted for proper methods of administration and associated precautions.

Dosage of goserelin acetate is expressed in terms of goserelin.

• Prostate Cancer

For the palliative treatment of advanced prostate cancer, the usual dosage of goserelin in men is 3.6 or 10.8 mg implanted subcutaneously every 4 or 12 weeks, respectively. For this indication, goserelin is intended for long-term administration unless it is clinically inappropriate.

When <a href="http://healthandprostate.com/drugs/goserelin-acetate-dosage" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/goserelin-acetate-dosage/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Flutamide</title>
		<link>http://healthandprostate.com/drugs/flutamide-4</link>
		<comments>http://healthandprostate.com/drugs/flutamide-4#comments</comments>
		<pubDate>Fri, 24 Jun 2011 09:00:24 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Bicalutamide]]></category>
		<category><![CDATA[Eulexin]]></category>
		<category><![CDATA[Flutamide]]></category>

		<guid isPermaLink="false">http://healthandprostate.com/?p=1040</guid>
		<description><![CDATA[C11H11F3N2O3 • Flutamide, a nonsteroidal antiandrogen, is an antineoplastic agent. Uses • Prostate Cancer Flutamide is used in combination with a gonadotropin-releasing hormone (GnRH) analog (e.g., goserelin, leuprolide acetate) in the treatment of prostate cancer that is clinically localized, such as that confined to the prostate but with extensive involvement of one lobe or with involvement of both lobes (stage B2) and that localized to the periprostatic area but extending beyond the capsule and possibly affecting seminal vesicles (stage C). Flutamide also is used in combination with a GnRH analog in the treatment of metastatic prostate cancer that involves distant lymph nodes, bone, or visceral organs (stage D2). For additional information on combined antiandrogenic and GnRH analog therapy. Prostate specific antigen (PSA) concentrations should be determined periodically during combined flutamide and GnRH analog therapy to monitor therapeutic response, including successful remission or possible progression of cancer. If PSA concentrations increase substantially and consistently Read more [...]]]></description>
			<content:encoded><![CDATA[C11H11F3N2O3

• Flutamide, a nonsteroidal antiandrogen, is an antineoplastic agent.
Uses
• Prostate Cancer

Flutamide is used in combination with a gonadotropin-releasing hormone (GnRH) analog (e.g., goserelin, leuprolide acetate) in the treatment of prostate cancer that is clinically localized, such as that confined to the prostate but with extensive involvement of one lobe or with involvement of both lobes (stage B2) and that localized to the periprostatic area but extending beyond the capsule and possibly affecting seminal vesicles (stage C). Flutamide also is used in combination with a GnRH analog in the treatment of metastatic prostate cancer that involves distant lymph nodes, bone, or visceral organs (stage D2). For additional information on combined antiandrogenic and GnRH analog therapy.

Prostate specific antigen (PSA) concentrations should be determined periodically during combined flutamide and GnRH analog therapy to monitor therapeutic response, including successful remission or possible progression of cancer. If PSA concentrations increase substantially and consistently <a href="http://healthandprostate.com/drugs/flutamide-4" class="more-link">Read more [...]</a>]]></content:encoded>
			<wfw:commentRss>http://healthandprostate.com/drugs/flutamide-4/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

